Aushon Biosystems

The company has developed a series of cytokine immunoassays for its Ciraplex platform that it said can achieve sensitivity in the femtogram per ml range.

NEW YORK (GenomeWeb) – Aushon Biosystems has been building up its IP portfolio ahead of a planned expansion to its Cira immunoassay platform.

Title: Method of and system for applying blocking material to assay substrates.
Patent Number: 8,685,486
Filed: Aug. 10, 2011

Richard Smith, director of proteomics at Pacific Northwest National Laboratory, has been named recipient of the 2013 Award for a Distinguished Contribution in Mass Spectrometry by the American Society for Mass Spectrometry.

People In The News

NEW YORK (GenomeWeb News) – Ariosa Diagnostics has appointed Michael Aicher to its board of directors. He is currently the CEO of Omicia. Previously, he was co-founder and CEO of the National Genetics Institute, a wholly owned subsidiary of Laboratory Corporation of America.

Agilent Technologies said this week that it has awarded its Agilent Thought Leader Award to Ronald DePinho, an oncologist at the University of Texas MD Anderson Cancer Center.

NEW YORK (GenomeWeb News) – Aushon BioSystems said today that it has appointed AH Diagnostics to be its exclusive distributor in Scandinavia, effective immediately.

BG Medicine has appointed Charles Abdalian to be executive VP and chief financial officer. Mike Rogers will be departing the company after three-and-a-half years as CFO.

Aushon BioSystems has appointed Martin Verhoef to be company CEO and to serve on its board of directors.

Aushon Biosystems of Billerica, Mass., has received US Patent No. 8,246,760, "Continual flow pin washer." The patent describes a multi-chambered deposition pin wash station that includes a lower chamber and an upper drain basin connected by wash tubes.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.